Dynavax (NASDAQ:DVAX) said that a recommendation from proxy advisory firm Glass Lewis against two of its director nominees is wrong. "Significant Board composition and strategy changes have already ...

Dynavax is kicking off May’s Hepatitis Awareness Month with a new push to improve education around hepatitis B and the benefits of vaccination. The company—which makes hepatitis B vaccine ...

Dynavax's net income dropped by 97% in Q2, 2023 compared to the previous year, but analysts praised management's performance. The company's HEPLISAV-B vaccine has exceeded expectations and is expected ...

EMERYVILLE, Calif., March 6, 2025 /PRNewswire/ — Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, has ...

EMERYVILLE, Calif., Feb. 19, 2025 /PRNewswire/ — Dynavax Technologies Corporation (Nasdaq: DVAX) (“Dynavax” or the “Company”), a commercial-stage biopharmaceutical company developing and ...

DYNAVAX INVESTOR ALERT: KAHN SWICK & FOTI, LLC INVESTIGATES ADEQUACY OF PRICE AND PROCESS IN PROPOSED SALE OF DYNAVAX TECHNOLOGIES CORPORATION - DVAX Former Attorney General of Louisiana Charles C.

Dynavax Technologies Corporation (NASDAQ:DVAX) announced topline results from Part 1 of its randomized, observer-blinded, and active-controlled Phase 1/2 clinical trial of Z-1018, a shingles vaccine ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Dynavax Technologies (DVAX) one of those stocks right now? A ...

The collaboration will combine Dynavax’s CpG 1018, the adjuvant contained in U.S. FDA-approved HEPLISAV-B vaccine, with Sinovac’s chemically inactivated coronavirus vaccine candidate CpG 1018 is the ...

Analysts are intrested in these 5 stocks: ( (DVAX)) and ( (IKT)). Here is a breakdown of their recent ratings and the rationale behind them. Dynavax (DVAX) has abruptly shifted from a growth story to ...

(Reuters) - Dynavax Technologies Inc may need to repitch its hepatitis B vaccine for a smaller patient population, after U.S. health regulators declined to approve the vaccine for adults - an ...